June 4, 2021

POINT Biopharma Announces First Patients Dosed in Phase 3 Study of PNT2002 for mCRPC

POINT today announced that it has successfully dosed multiple patients in its Phase 3 SPLASH study evaluating the efficacy of PNT2002, the Company’s investigational 177Lu-PSMA targeted radioligand therapy.

April 28, 2021

POINT Biopharma Receives U.S. Nuclear Regulatory Commission Materials License for Indiana Facility

Globally focused radiopharmaceutical company achieves significant milestone to accelerate the operationalization of their 80,000 sq ft radioligand manufacturing facility

March 23, 2021

POINT Biopharma and TerraPower Sign Supply Agreement for Actinium-225

POINT announced today they signed a research and clinical supply agreement with TerraPower for the medical radioisotope actinium-225 (Ac-225)

March 15, 2021

Next-generation Radiopharmaceuticals Company POINT Biopharma to list on NASDAQ through merger with Research Alliance Corp. I

POINT Biopharma has entered into a definitive merger agreement with Research Alliance Corp. I (Nasdaq: RACA). Upon closing, the combined company is expected to be listed on Nasdaq under the ticker symbol “PNT”.

January 12, 2021

POINT Biopharma signs exclusive license agreement with CanProbe for the commercialization of a neuroendocrine tumor treatment

Today it was announced that POINT has signed a licensing and commercialization agreement with CanProbe for exclusive rights to Lutetium – 177 Octreotate (Lu-DOTATATE) for the treatment of neuroendocrine cancer.